Business News

Sanofi and Kymera Therapeutics Enter Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

CAMBRIDGE, Mass., July 9, 2020 /PRNewswire/ — Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage …

Read More »

ProteinQure and AstraZeneca Collaborate to Design Novel Peptide Therapeutics

TORONTO–(BUSINESS WIRE)–ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics. Peptide therapeutics have unique properties that make them highly effective …

Read More »

Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Takeda Pharmaceutical Company Limited (Takeda) for access to proprietary phage display libraries for the discovery, validation and optimization of …

Read More »

Xencor and Atreca Partner to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on …

Read More »

Merck and Foghorn Collaborate to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada. The collaboration will apply Foghorn’s proprietary Gene Traffic Control™ product platform …

Read More »

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

CARLSBAD, Calif., July 8, 2020 /PRNewswire/ — Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test …

Read More »

Dragonfly Therapeutics Collaborates with Bristol Myers Squibb to Develop Novel Therapeutics for Multiple Sclerosis and Neuro-inflammation Targets

WALTHAM, Mass., July 6, 2020 /PRNewswire/— Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a new research collaboration with Bristol Myers Squibb to discover and develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets. Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property …

Read More »

Numab Therapeutics and Boehringer Ingelheim Partner to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

INGELHEIM, Germany & WAEDENSWIL, Switzerland–(BUSINESS WIRE)–Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal …

Read More »

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program from Gilead

DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus …

Read More »

MEI Pharma and Helsinn Group Discontinue Phase 3 Study of Pracinostat in AML After Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of …

Read More »